Limited efficacy of daratumumab in multiple myeloma with extramedullary disease

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	JELINEK Tomas SEVCIKOVA Tereza ZIHALA David POPKOVA Tereza KAPUSTOVA Veronika BROSKEVICOVA Lucie CAPKOVA Lenka ŘÍHOVÁ Lucie BEZDĚKOVÁ Renata ŠEVČÍKOVÁ Sabina ZIDLIK Vladimir HAVEL Martin PLONKOVA Hana JUNGOVA Alexandra MINARIK Jiri ŠTORK Martin POUR Luděk PAVLICEK Petr SPICKA Ivan MAISNAR Vladimir RADOCHA Jakub SIMICEK Michal HAJEK Roman
Year of publication	2022
Type	Article in Periodical
Magazine / Source	Leukemia
MU Faculty or unit	Faculty of Medicine
Citation
Web	https://www.nature.com/articles/s41375-021-01343-w
Doi	http://dx.doi.org/10.1038/s41375-021-01343-w
Keywords	daratumumab; multiple myeloma; extramedullary disease; efficacy
Description	The treatment of multiple myeloma (MM) has changed substantially during the past two decades. The incorporation of novel agents into therapeutic strategies has resulted in prolonged overall survival of MM patients with approximately 15% of them being considered operationally cured.
Related projects:	Analýza mikroprostředí kostní dřeně u extramedulárního relapsu mnohočetného myelomu e-Infrastruktura CZ